An update to HLA Nomenclature, 2010

Marsh, S. G. E.; Albert, E. D.; Bodmer, W F; Bontrop, Ronald E.; Dupont, Bo; Erlich, H.A.; Fernández-Viña, Marcelo; Geraghty, Dan; Holdsworth, Rhonda; Hurley, C K; Lau, Marie; Lee, Kw W.; Mach, Bernard; Maiers, Martin; Mayr, W. R.; Müller, C. R.; Parham, Peter; Petersdorf, EW; Sasazuki, Takehiko; Strominger, J L; Svejgaard, A.; Terasaki, P. I.; Jm, Tiercy; Trowsdale, John

doi:10.1038/bmt.2010.79

Cited by 50 publications

(32 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We selected 509 donorrecipient pairs for whom we had molecular HLA-A, -B, -C, and -DRB1 typing at an antigen (ie, first field; N 5 335) or allelic (ie, second field; N 5 174) resolution level. 31 Haploidentical donors were defined as first-degree relatives who shared 1 HLA haplotype and were mismatched at 1 or more loci on the unshared haplotype.…”

Section: Collection Of Data and Inclusion Criteriamentioning

confidence: 99%

The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis

Lorentino¹,

Labopin

Fleischhauer

et al. 2017

Blood Advances

View full text Add to dashboard Cite

Key Points• In unmanipulated haplo-HSCT, antigenic HLA-DRB1 match, stem cell source, conditioning, and donor sex are associated with GVHD.• The role of HLAmatching status and other factors influencing alloreactivity is more prominent with PTCy compared to ATG GVHD prophylaxis.Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with unmanipulated grafts is increasingly adopted for high-risk acute leukemia, with acute graft-versus-host Moreover, the hazards of aGVHD were significantly associated with other factors influencing alloreactivity, including peripheral blood as stem cell source (HR, 2.2; 95% CI, 1.4-3; P , .01), reduced-intensity conditioning (HR, 0.6; 95% CI, 0.4-0.9; P 5 .04), and female donors (HR, 1.8; 95% CI, 1-3.2; P 5 .05), in PTCy but not ATG regimens. No significant associations were found between cumulative number of HLA mismatches and GVHD, or between HLA-matching status and other study end points including transplant-related mortality, disease-free survival, and relapse. Based on these data, the role of HLA mismatching on unshared haplotype appears not to be sufficiently prominent to justify its consideration in haploidentical donor selection. However, the role of HLA matching in haploidentical HSCT might be modulated by GVHD prophylaxis, calling for further investigations in this increasingly relevant field.

show abstract

Section: Collection Of Data and Inclusion Criteriamentioning

confidence: 99%

The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis

Lorentino¹,

Labopin

Fleischhauer

et al. 2017

Blood Advances

View full text Add to dashboard Cite

show abstract

“…MICA is polymorphic, 72 has strong haplotypic associations to HLA-B, 73,74 is inducible by stress, 75 and is a ligand for activating NKG2D receptors. 76 A potential role for MICA in GVHD might involve T cell-or NK-mediated pathways and/or inflammatory and stress mediators.…”

Section: Micamentioning

confidence: 99%

The major histocompatibility complex: a model for understanding graft-versus-host disease

Petersdorf

2013

Blood

View full text Add to dashboard Cite

Acute graft-versus-host disease (GVHD) afflicts as much as 80% of all patients who receive an unrelated donor hematopoietic cell transplant (HCT) for the treatment of blood disorders, even with optimal donor HLA matching and use of prophylactic immunosuppressive agents. Of patients who develop acute GVHD, many are at risk for chronic GVHD and bear the burden of considerable morbidity and lowered quality of life years after transplantation. The immunogenetic basis of GVHD has been the subject of intensive investigation, with the classic HLA genetic loci being the best-characterized determinants. Recent information on the major histocompatibility complex (MHC) region of chromosome 6 as an important source of untyped genetic variation has shed light on novel GVHD determinants. These data open new paradigms for understanding the genetic basis of GVHD.

show abstract

“…Moreover, new group codes were introduced representing all expressed alleles leading to identical protein sequences (P suffix after two fields) or alleles with identical nucleotide sequences (G suffix after three fields) in the exon(s) encoding the Ag-recognition site. 9,10 This update takes into account all the above changes and extensions leading to modifications throughout the guideline document. The Information Technology Working Group is continuously monitoring and vetting new approaches for capturing genetic data in a more primary format that is not impacted by nomenclature changes and deals with HLA ambiguity in ways that are more generic, open and rule-driven.…”

Section: Introductionmentioning

confidence: 99%

“…7,8 UPDATE TO THE WMDA HLA NOMENCLATURE GUIDELINES An update to these standards became necessary because of the major revision of the World Health Organization (WHO) HLA nomenclature in April 2010. 9,10 Moreover, other issues seriously hampering the smooth electronic exchange of HLA-typing data were addressed. The updated version of the WMDA HLA Nomenclature Guidelines was approved by the WMDA Board in May 2012.…”

Section: Introductionmentioning

confidence: 99%

An update to the HLA Nomenclature Guidelines of the World Marrow Donor Association, 2012

Bochtler

Maiers

Bakker

et al. 2013

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

For more than two decades, international cooperation and information technology have been playing key roles in the identification of suitable unrelated donors and cord blood units for hematopoietic SCT. To ensure consistent coding and interpretation of HLA data among the linked computer systems, the World Marrow Donor Association has standardized the extensions of the World Health Organization (WHO) Nomenclature for factors of the HLA system applied in practice. The first version of this report published in 2007 has become the reference for the technical validation of HLA information on donors and patients in the context of search and matching and is used by registries of volunteer unrelated hematopoietic stem cell donors and umbilical cord blood banks throughout the world. The present update became necessary after the major revision of the WHO HLA nomenclature in April 2010. It now covers issues arising when alleles are withdrawn or renamed because of the continuous updating of the WHO HLA nomenclature. In addition, formal validation and interpretation rules for the so-called 'multiple allele codes' have been added.

show abstract

An update to HLA Nomenclature, 2010

Cited by 50 publications

References 7 publications

The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis

The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis

The major histocompatibility complex: a model for understanding graft-versus-host disease

An update to the HLA Nomenclature Guidelines of the World Marrow Donor Association, 2012

Contact Info

Product

Resources

About